Related Experiment Videos
Adenovirus-mediated gene transfer to the brain: methodological assessment
E Peltékian1, E Parrish, C Bouchard
1INSERM Unit 421, Faculté de Médecine, Créteil, France.
Journal of Neuroscience Methods
|January 1, 1997
Summary
Adenovirus vectors show promise for brain gene therapy due to broad cell targeting and long-term expression. However, cell death and toxicity issues must be addressed for treating neurodegenerative diseases and brain tumors.
Area of Science:
- Neuroscience
- Gene Therapy
- Virology
Background:
- Adenovirus (Ad) vectors are explored for gene transfer to the brain.
- Understanding Ad transduction characteristics is crucial for therapeutic applications.
Purpose of the Study:
- To analyze the advantages and limitations of adenovirus as a gene transfer vector for the brain.
- To evaluate the potential of Ad-mediated gene therapy for central nervous system disorders.
Main Methods:
- Review of existing literature on adenovirus transduction in the central nervous system.
- Analysis of Ad vector properties including cell specificity, spatial spread, and transgene expression.
- Examination of cell death mechanisms and toxicity associated with Ad transduction in the brain.
Main Results:
- Adenovirus vectors exhibit broad cell type targeting and enable long-term transgene expression.
- Unlike other organs, Ad transduction in the adult brain does not consistently cause cell death, but some cell death does occur.
- Potential causes of cell death include immune rejection, inflammation, and direct vector toxicity.
Conclusions:
- Adenovirus vectors may be suitable for life-threatening brain conditions like malignant tumors and neurodegenerative diseases (Huntington's, Alzheimer's, ALS) lacking effective treatments.
- Gene therapy using adenovirus vectors is less advisable for non-life-threatening conditions or those with existing treatments (Parkinson's, epilepsy).
- Further optimization of adenovirus vectors and gene targets is necessary for safe and effective brain gene therapy.